



Announcement Summary

Entity name

IMMUTEP LIMITED

Announcement Type

New announcement

Date of this announcement

22/11/2023

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
IMMAM	PERFORMANCE RIGHTS	768,311

Proposed +issue date

23/11/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

IMMUTEP LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ACN

Registration Number

009237889

1.3 ASX issuer code

IMM

1.4 The announcement is

New announcement

1.5 Date of this announcement

22/11/2023

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	24/10/2023	<input checked="" type="checkbox"/> Actual	Yes

Comments

Shareholders approved the issuance of 178,356 Performance Rights to Dr Howard and 589,955 Performance Rights to Ms Boyce in lieu of cash for directors' fees at the Company's AGM on 24 Oct 2023.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

 Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

 No

Details of +securities proposed to be issued

ASX +security code and description

IMMAM : PERFORMANCE RIGHTS

Number of +securities proposed to be issued

768,311

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

 No



Please describe the consideration being provided for the +securities

The issue of Performance Rights to subscribe for 178,356 ordinary shares in the Company to Dr Howard as an increase in his remuneration for his services as a Director of the Company and in lieu of additional cash for Directors' fees to vest as follows:

- 28,356 on 24 Oct 2023. (for service from 1 Apr 2023 to 23 Oct 2023);
- 50,000 on 1 Dec 2024. (for service from 24 Oct 2023 to 23 Oct 2024);
- 50,000 on 1 Dec 2025. (for service from 24 Oct 2024 to 23 Oct 2025).
- 50,000 on 1 Dec 2026. (for service from 24 Oct 2025 to 23 Oct 2026).

The issue of Performance Rights to subscribe for 589,955 ordinary shares in the Company to Lis Boyce in lieu of cash for directors' fees to vest as follows:

- 89,954 on 24 Oct 2023. (for service from 1 Apr 2023 to 23 Oct 2023);
- 166,667 on 1 Dec 2024. (for service from 24 Oct 2023 to 23 Oct 2024);
- 166,667 on 1 Dec 2025. (for service from 24 Oct 2024 to 23 Oct 2025).
- 166,667 on 1 Dec 2026. (for service from 24 Oct 2025 to 23 Oct 2026).

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

222,810.190000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 7C - Timetable

7C.1 Proposed +issue date

23/11/2023

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

24/10/2023

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No



Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

No

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

N/A

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

178,356 Performance Rights issued to Dr Howard in lieu of cash for an increase in directors fees of \$16.5k p.a. and 589,955 Performance Rights issued to Ms Boyce in lieu of cash for directors' fees of \$55k p.a. as approved at the AGM on 24 Oct 2023.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

N/A